{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:56:25Z","timestamp":1793735785714,"version":"4.6.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>To determine the impact of CYP2C19 genotyping on the occurrence of major adverse cardiovascular events (MACE), in cohort of Iraqi patients on clopidogrel after percutaneous coronary intervention (PCI), a total of 201 Iraqi patients undergoing the latter procedure were enrolled. All enrollees had their CYP2C19 genotyped using polymerase chain reaction and reverse hybridization. Genotyping revealed that CYP2C19 *1, *17, *2, and *8 allele frequencies were, respectively, 0.604, 0.276, 0.117, and 0.0026. After the exclusion of those with 2 loss of function alleles, 186 patients were available for follow-up as long as they were on clopidogrel, or until MACE occurred, which was encountered in 8.6% after a median of 12 months. Among predictors associated with MACE was the carriage of one CYP2C19 loss of function allele {hazard ratio (HR) 8.6 [confidence interval (CI) 3.15\u201323.4]; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0005}, hypertension [HR 3.74 (CI 1.06\u201313.16); <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04], reduced ventricular function [HR 3.88 (1.43\u201310.54); <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.008], and history of previous myocardial infarction [HR 4.9 (CI 1.48\u201311.33); <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.007] by univariate analysis, although only CYP2C19 genotype remained significant by multivariate analysis [HR 11.88 (CI 3.25\u201343.44); <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0005]. The latter observation favors CYP2C19 genotype\u2013guided antiplatelet therapy and extending the use of alternative antiplatelet drugs to those with single loss of function allele after percutaneous coronary intervention.<\/jats:p>","DOI":"10.1097\/fjc.0000000000000577","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T20:49:25Z","timestamp":1521233365000},"page":"347-351","source":"Crossref","is-referenced-by-count":10,"title":["CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention"],"prefix":"10.1097","volume":"71","author":[{"given":"Ameen M.","family":"Mohammad","sequence":"first","affiliation":[{"name":"Internal Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir A. S.","family":"Al-Allawi","sequence":"additional","affiliation":[{"name":"Pathology, College of Medicine, University of Duhok, Kurdistan, Iraq."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.4244\/EIJY14M09_01","article-title":"2014 ESC\/EACTS guidelines on myocardial revascularization","volume":"10","author":"Windecker","year":"2015","journal-title":"EuroInterv."},{"key":"R2-20230911","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization","volume":"31","author":"Wijns","year":"2010","journal-title":"Eur Heart J."},{"key":"R3-20230911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-016-0436-7","article-title":"The burden of major adverse cardiac events in patients with coronary artery disease","volume":"17","author":"Tsai","year":"2017","journal-title":"BMC Cardiovasc Disord."},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"e0121620","DOI":"10.1371\/journal.pone.0121620","article-title":"Evaluation of clinical risk factors to predict high on treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE)","volume":"10","author":"Droppa","year":"2015","journal-title":"PLoS One."},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood."},{"key":"R6-20230911","first-page":"236","article-title":"Clopidogrel resistance: current aspects and future directions","volume":"52","author":"Vlachojannis","year":"2011","journal-title":"Hellenic J Cardiol."},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/cts.12383","article-title":"Genetic and nongenetic factors affecting clopidogrel response in the Egyptian population","volume":"9","author":"Khalil","year":"2016","journal-title":"Clin Transl Sci."},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-0038-1648859","article-title":"The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A","volume":"72","author":"Savi","year":"1994","journal-title":"Thromb Haemost."},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1479-7364-4-4-278","article-title":"The human cytochrome P450 (CYP) allele nomenclature website: a peer-reviewed database of CYP variants and their associated effects","volume":"4","author":"Sim","year":"2010","journal-title":"Hum Genomics."},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ihj.2012.06.003","article-title":"CYP2C19*2\/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?","volume":"64","author":"Singh","year":"2012","journal-title":"Indian Heart J."},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced function CYP2C19 genotype and the risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. A meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA."},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/14622416.9.6.691","article-title":"Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China","volume":"9","author":"Chen","year":"2008","journal-title":"Pharmacogenomics."},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2133\/dmpk.21.286","article-title":"CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations","volume":"21","author":"Tassaneeyakul","year":"2006","journal-title":"Drug Metab Pharmacokinet."},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2133\/dmpk.DMPK-11-RV-111","article-title":"Population differences in major functional polymorphisms of pharmacokinetics\/pharmacodynamics-related genes in Eastern Asians and Europeans: Implications in the clinical trials for novel drug development","volume":"27","author":"Kurose","year":"2012","journal-title":"Drug Metab Pharmacokinet."},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-004-0890-5","article-title":"Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study","volume":"61","author":"Bravo-Villalta","year":"2005","journal-title":"Eur J Clin Pharmacol."},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12041-015-0581-2","article-title":"Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations","volume":"94","author":"Abdelhedi","year":"2015","journal-title":"J Genet."},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.7150\/ijms.6795","article-title":"Genotype-Phenotype analysis of CYP2C19 in healthy Saudi Individuals and its potential clinical implication in Drug therapy","volume":"10","author":"Saeed","year":"2013","journal-title":"Int J Med Sci."},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther."},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00228-006-0183-2","article-title":"Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients","volume":"62","author":"Kurzawski","year":"2006","journal-title":"Eur J Clin Pharmacol."},{"key":"R21-20230911","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5144\/0256-4947.2012.9","article-title":"Baseline characteristics, management practices, and long-term outcomes of middle eastern patients in the second Gulf registry of acute coronary events (Gulf RACE-2)","volume":"32","author":"Alhabib","year":"2012","journal-title":"Ann Saudi Med."},{"key":"R22-20230911","first-page":"25","article-title":"Relation of cardiovascular risk factors with coronary angiographic findings in Iraqi patients with ischemic heart disease","volume":"1","author":"Mohammad","year":"2013","journal-title":"Am J Cardiovasc Dis Res."},{"key":"R23-20230911","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/eurheartj\/ehl196","article-title":"The second euro heart survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004","volume":"27","author":"Mandelzweig","year":"2006","journal-title":"Euro Heart J."},{"key":"R24-20230911","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA."},{"key":"R25-20230911","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med."},{"key":"R26-20230911","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Par\u00e9","year":"2010","journal-title":"N Engl J Med."},{"key":"R27-20230911","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J."},{"key":"R28-20230911","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"R29-20230911","doi-asserted-by":"crossref","first-page":"e102701","DOI":"10.1371\/journal.pone.0102701","article-title":"Interplay between genetic and clinical variables affecting platelets reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention","volume":"9","author":"Siller-Matula","year":"2014","journal-title":"PLoS One."},{"key":"R30-20230911","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12872-016-0454-5","article-title":"Impact of diabetes and hypertension on cardiovascular outcome in patients with coronary artery disease receiving percutaneous coronary intervention","volume":"17","author":"Lin","year":"2017","journal-title":"BMC Cardiovasc Dis."},{"key":"R31-20230911","first-page":"174","article-title":"Efficacy and safety of drug-eluting stents in the real world: 8 year follow-up","volume":"103","author":"Pelligrini","year":"2014","journal-title":"Arq Bras Cardiol."},{"key":"R32-20230911","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/FPC.0b013e3282f1b2be","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G\/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients","volume":"17","author":"Giusti","year":"2007","journal-title":"Pharmacogenet Genomics."},{"key":"R33-20230911","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet."},{"key":"R34-20230911","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000457947","article-title":"Genotyping, platelet activation, and cardiovascular outcome in patients after percutaneous coronary intervention: two pieces of the puzzle of clopidogrel resistance","volume":"137","author":"Siasos","year":"2017","journal-title":"Cardiology."},{"key":"R35-20230911","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1253\/circj.72.1165","article-title":"Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel","volume":"72","author":"Malek","year":"2008","journal-title":"Circ J."},{"key":"R36-20230911","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic sub-study of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet."},{"key":"R37-20230911","first-page":"241","article-title":"Factors affecting outcome of primary percutaneous intervention for acute myocardial infarction","volume":"9","author":"Sadrnia","year":"2013","journal-title":"ARYA Atheroscler."},{"key":"R38-20230911","first-page":"7","article-title":"The impact of hypertension on patients with acute coronary syndrome","volume":"2011","author":"Picariello","year":"2011","journal-title":"Int J Hypertenion."},{"key":"R39-20230911","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ahj.2010.09.030","article-title":"The association of sex with outcomes among patients undergoing percutaneous coronary intervention for ST elevating myocardial infarction in the contemporary era: insights from the blue cross shield of Michigan Cardiovascular consortium (BMC2)","volume":"161","author":"Jackson","year":"2011","journal-title":"Am Heart J."},{"key":"R40-20230911","doi-asserted-by":"crossref","first-page":"552","DOI":"10.18553\/jmcp.2015.21.7.552","article-title":"Financial analysis of CYP2C19 genotyping in patients receiving dual antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention","volume":"21","author":"Johnson","year":"2015","journal-title":"J Manag Care Spec Pharma."},{"key":"R41-20230911","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10557-016-6705-y","article-title":"CYP2C19 LOF and GOF-Guided antiplatelet therapy in patients with acute coronary syndrome: a cost-effectiveness analysis","volume":"31","author":"Jiang","year":"2017","journal-title":"Cardiovasc Drugs Ther."},{"key":"R42-20230911","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2012.04639.x","article-title":"Phenotyping vs genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study","volume":"10","author":"Siller-Matula","year":"2012","journal-title":"J Thromb Haemost."},{"key":"R43-20230911","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/VHRM.S44469","article-title":"Platelet function tests: a comparative review","volume":"11","author":"Paniccia","year":"2015","journal-title":"Vasc Health Risk Manag."},{"key":"R44-20230911","doi-asserted-by":"crossref","first-page":"10176","DOI":"10.1038\/ncomms10176","article-title":"A shear gradient-activated microfluidic test for automated monitoring of whole blood haemostasis and platelet function","volume":"7","author":"Jain","year":"2016","journal-title":"Nat Commun."},{"key":"R45-20230911","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-0036-1597298","article-title":"Monitoring antiplatelet therapy","volume":"43","author":"Orma","year":"2017","journal-title":"Semin Thromb Hemost."}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005344-201806000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T01:15:47Z","timestamp":1694394947000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005344-201806000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0000000000000577","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}